Secondary bleeding outcomes
| Outcome . | Phenotype of platelet donor . | |||
|---|---|---|---|---|
| Unselected (n = 28) . | High responder ( n = 49) . | Low responder (n = 51) . | ||
| Difference from unselected group . | Difference from unselected group . | Difference from high-responder group . | ||
| Patients with grade 2-4 bleed: clinical assessment, no. (%) | 7 (25) | 10 (20) | 9 (18) | |
| Odds ratio (95% CI) | NA | 0.84 (0.28, 2.56) | 0.66 (0.21, 2.03) | 0.78 (0.29, 2.16) |
| P | NA | .76 | .47 | .64 |
| Patients with grade 2-4 bleed: patient self-assessment, no. (%) | 8 (29) | 16 (33) | 21 (41) | |
| Odds ratio (95% CI) | NA | 1.27 (0.45, 3.53) | 1.92 (0.70, 5.25) | 1.51 (0.66, 3.49) |
| P | NA | .65 | .20 | .33 |
| Days with grade 2-4 bleed: clinical assessment, median (IQR) | 0 (0-1) | 0 (0-0) | 0 (0-0) | |
| Rate ratio (95% CI) | NA | 0.66 (0.13, 3.41) | 0.46 (0.09, 2.30) | 0.70 (0.16, 2.97) |
| P | NA | .62 | .34 | .63 |
| Days with grade 2-4 bleed: patient self-assessment, median (IQR) | 0 (0-1) | 0 (0-1) | 0 (0-1) | |
| Rate ratio (95% CI) | NA | 0.86 (0.25, 2.98) | 1.05 (0.31, 3.52) | 1.26 (0.53, 3.00) |
| P | NA | .81 | .94 | .60 |
| Red cell transfusions, median (IQR) | 0 (0-1) | 1 (0-1) | 0 (0-1) | |
| Rate ratio (95% CI) | NA | 1.27 (0.64, 2.53) | 0.78 (0.38, 1.62) | 0.60 (0.33, 1.08) |
| P | NA | .49 | .50 | .09 |
| Time from randomization to next platelet transfusion, median (IQR), d | 3 (2-3) | 3 (2-4) | 3 (3-4) | |
| Hazard ratio (95% CI) | NA | 0.85 (0.47, 1.55) | 0.68 (0.36, 1.28) | 0.81 (0.49, 1.34) |
| P | NA | .60 | .23 | .42 |
| Outcome . | Phenotype of platelet donor . | |||
|---|---|---|---|---|
| Unselected (n = 28) . | High responder ( n = 49) . | Low responder (n = 51) . | ||
| Difference from unselected group . | Difference from unselected group . | Difference from high-responder group . | ||
| Patients with grade 2-4 bleed: clinical assessment, no. (%) | 7 (25) | 10 (20) | 9 (18) | |
| Odds ratio (95% CI) | NA | 0.84 (0.28, 2.56) | 0.66 (0.21, 2.03) | 0.78 (0.29, 2.16) |
| P | NA | .76 | .47 | .64 |
| Patients with grade 2-4 bleed: patient self-assessment, no. (%) | 8 (29) | 16 (33) | 21 (41) | |
| Odds ratio (95% CI) | NA | 1.27 (0.45, 3.53) | 1.92 (0.70, 5.25) | 1.51 (0.66, 3.49) |
| P | NA | .65 | .20 | .33 |
| Days with grade 2-4 bleed: clinical assessment, median (IQR) | 0 (0-1) | 0 (0-0) | 0 (0-0) | |
| Rate ratio (95% CI) | NA | 0.66 (0.13, 3.41) | 0.46 (0.09, 2.30) | 0.70 (0.16, 2.97) |
| P | NA | .62 | .34 | .63 |
| Days with grade 2-4 bleed: patient self-assessment, median (IQR) | 0 (0-1) | 0 (0-1) | 0 (0-1) | |
| Rate ratio (95% CI) | NA | 0.86 (0.25, 2.98) | 1.05 (0.31, 3.52) | 1.26 (0.53, 3.00) |
| P | NA | .81 | .94 | .60 |
| Red cell transfusions, median (IQR) | 0 (0-1) | 1 (0-1) | 0 (0-1) | |
| Rate ratio (95% CI) | NA | 1.27 (0.64, 2.53) | 0.78 (0.38, 1.62) | 0.60 (0.33, 1.08) |
| P | NA | .49 | .50 | .09 |
| Time from randomization to next platelet transfusion, median (IQR), d | 3 (2-3) | 3 (2-4) | 3 (3-4) | |
| Hazard ratio (95% CI) | NA | 0.85 (0.47, 1.55) | 0.68 (0.36, 1.28) | 0.81 (0.49, 1.34) |
| P | NA | .60 | .23 | .42 |
Differences in means are high response vs low response.